search
Back to results

Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema

Primary Purpose

Emphysema

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Hypoxia administration study group
Hyperoxia administration study group
Sildenafil
Sponsored by
Eric A. Hoffman
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Emphysema

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Must be between the ages of 25 and 65.
  2. Must be currently smoking at least 1/2 pack/day (confirmed with cotinine level).
  3. Must have pulmonary function test (PFT) results that meet the following (there will be two groups):

    Group 1:

    • Forced expiratory volume at one second (FEV1)/Forced vital capacity (FVC) > 70%
    • Forced Expiratory Flow at 25-75% of predicted(FEF25-75) > 79% of predicted
    • FVC greater than 80% of predicted

    Group 2:

    For subjects with mild lung impairment:

    • FEV1>80% of predicted
    • FEV1/FVC<0.7
  4. Must be able to give informed consent for self.

Exclusion Criteria:

  1. Pregnant or breastfeeding females.
  2. Body Mass Index (BMI) greater than 32.
  3. Weight of greater than 220 pounds (100 kg).
  4. Allergies to shell fish, seafood, eggs or iodine.
  5. Heart disease, kidney disease or diabetes.
  6. Diagnosis of asthma.
  7. Usage of any medications that are known to affect the heart or lungs (contraceptives, anti-depressants, analgesics EXCEPT aspirin, antihypertensives, and medications for osteoporosis and gastrointestinal diseases will be allowed).
  8. Any metal in or on the body between the nose and the abdomen.
  9. Any major organ system disease (by judgment of study medical team).
  10. A glomerular filtration rate of 60 cc per minute or less.

For the subjects that will receive Sildenafil as part of the study, additional exclusion criteria are as follows:

  1. Nitroglycerin usage or nitrates (in addition to nitroglycerin) and use of phosphodiesterase 5 (PDE5) inhibitors within the previous 7 days of the study date.
  2. Prior history of hypersensitivity to Sildenafil.

Sites / Locations

  • University of IowaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Hypoxia Administration study group

Hyperoxia Administration study group

Sildenafil

Arm Description

40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.

40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.

40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.

Outcomes

Primary Outcome Measures

Perfused blood volume assessed pre and post sildenafil administration
Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post the administration of sildenafil.
Perfused blood volume assessed pre and post hyperoxic breathing
Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post hyperoxic breathing
Perfused blood volume assessed pre and post hypoxic breathing
Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post hypoxic breathing

Secondary Outcome Measures

Full Information

First Posted
January 12, 2016
Last Updated
July 12, 2023
Sponsor
Eric A. Hoffman
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT02682147
Brief Title
Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema
Official Title
Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 10, 2017 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
February 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Eric A. Hoffman
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will use dual energy x-ray computed tomography (DECT) to evaluate the relationship between heterogeneous perfusion, hypoxia (low oxygen in inspired gas) and induction of pulmonary vascular dilatation to characterize emphysema susceptibility in a normal smoking population. The investigators will correlate DECT measures of perfusion with lung injury measured by single photon emission computed tomography (SPECT). The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema
Detailed Description
Imaging-based metrics have recently played a central role in the quest to identify chronic obstructive pulmonary disease (COPD) phenotypes, serving to establish homogeneous sub-populations to aid in genotyping, therapeutic targeting and design and outcomes assessment. Recent findings in both animals and humans have lead us to believe that CT derived perfusion (PBF) and mean transit time (MTT) measures within regionally injured lung parenchyma provide for a functional phenotype of which may be directly tied to the etiology of the pathologic process leading to emphysema in acentrilobular emphysema susceptible subset of the smoking population. The primary hypotheses of the proposal are built around the notion that smokers prone to emphysema have abnormal vasoregulation in that regional hypoxic pulmonary vasoconstriction (HPV) continues despite regional lung injury. This failure to block vasoconstriction alters the repair response and leads to tissue destruction in emphysema susceptible smokers (SS) with abnormal vasoregulation. The normal response to regional hypoxia is to shunt blood towards better-ventilated regions. However, smoking induces small scale, regional infiltrates which in turn lead to local hypoxia, HPV would interfere with defense mechanisms serving to clear the irritant and thus interfere with mechanisms of repair. The investigators have demonstrated that, in SS subjects with normal PFTs but CT evidence of early centriacinar emphysema (CAE), there is an increased heterogeneity of perfusion. This is supportive of the notion that attenuation of vasoconstriction has failed. Further, the investigators have demonstrated a tight correlation between quantitative CT evidence of emphysema with reduced lung volume (LV) filling down to very small amounts of emphysema. The investigators outline a series of experiments seeking to: link increased pulmonary perfusion heterogeneity in SS subjects to the lung's response to alveolar oxygenation; establish that the perfusion heterogeneity is reversible; demonstrate that the response to inflammation and not just inflammation itself is a key factor in the increased heterogeneity. With any combination of positive outcomes of this study, the investigators will have provided new insights into disease etiology, serving to provide new targets for disease intervention and providing the tools needed for assessing outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Emphysema

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Hypoxia Administration study group
Arm Type
Experimental
Arm Description
40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.
Arm Title
Hyperoxia Administration study group
Arm Type
Experimental
Arm Description
40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.
Arm Title
Sildenafil
Arm Type
Experimental
Arm Description
40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
Intervention Type
Drug
Intervention Name(s)
Hypoxia administration study group
Other Intervention Name(s)
Oxygen
Intervention Description
scan completed after 5 minutes of breathing in hypoxic air
Intervention Type
Drug
Intervention Name(s)
Hyperoxia administration study group
Other Intervention Name(s)
Oxygen
Intervention Description
scan completed after up to 15 minutes of breathing in hyperoxic air
Intervention Type
Drug
Intervention Name(s)
Sildenafil
Other Intervention Name(s)
Revatio
Intervention Description
One dose of 20 mg Sildenafil will be given one hour before CT imaging.
Primary Outcome Measure Information:
Title
Perfused blood volume assessed pre and post sildenafil administration
Description
Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post the administration of sildenafil.
Time Frame
Pre sildenafil adminstration and one hour after sildenafil adminstration.
Title
Perfused blood volume assessed pre and post hyperoxic breathing
Description
Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post hyperoxic breathing
Time Frame
Pre hyperoxic breathing and 15 minutes post hyperoxic breathing
Title
Perfused blood volume assessed pre and post hypoxic breathing
Description
Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post hypoxic breathing
Time Frame
Pre hypoxic breathing and 15 minutes post hypoxic breathing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Must be between the ages of 25 and 65. Must be currently smoking at least 1/2 pack/day (confirmed with cotinine level). Must have pulmonary function test (PFT) results that meet the following (there will be two groups): Group 1: Forced expiratory volume at one second (FEV1)/Forced vital capacity (FVC) > 70% Forced Expiratory Flow at 25-75% of predicted(FEF25-75) > 79% of predicted FVC greater than 80% of predicted Group 2: For subjects with mild lung impairment: FEV1>80% of predicted FEV1/FVC<0.7 Must be able to give informed consent for self. Exclusion Criteria: Pregnant or breastfeeding females. Body Mass Index (BMI) greater than 32. Weight of greater than 220 pounds (100 kg). Allergies to shell fish, seafood, eggs or iodine. Heart disease, kidney disease or diabetes. Diagnosis of asthma. Usage of any medications that are known to affect the heart or lungs (contraceptives, anti-depressants, analgesics EXCEPT aspirin, antihypertensives, and medications for osteoporosis and gastrointestinal diseases will be allowed). Any metal in or on the body between the nose and the abdomen. Any major organ system disease (by judgment of study medical team). A glomerular filtration rate of 60 cc per minute or less. For the subjects that will receive Sildenafil as part of the study, additional exclusion criteria are as follows: Nitroglycerin usage or nitrates (in addition to nitroglycerin) and use of phosphodiesterase 5 (PDE5) inhibitors within the previous 7 days of the study date. Prior history of hypersensitivity to Sildenafil.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Debra J OConnell Moore, MBA
Phone
319-356-1693
Email
debra-oconnell-moore@uiowa.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Sue E Salisbury, BS
Phone
319-356-1810
Email
sue-salisbury@uiowa.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric A Hoffman, PhD
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Debra O'Connell-Moore, BS
Phone
319-356-1785
Email
debra-oconnell-moore@uiowa.edu
First Name & Middle Initial & Last Name & Degree
Ann Thompson
Phone
319-353-6213
Email
ann-thompson@uiowa.edu
First Name & Middle Initial & Last Name & Degree
Eric A Hoffman, Ph.D.

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
CT images will be shared including non-contrast images at TLC, FRC and RV as well as dual energy CT image data used to assess regional perfused blood volume. All associated pulmonary function test results will be shared. CT-derived metrics
IPD Sharing Time Frame
Data will be made available starting 6 months after publication of the primary results of each aim.
IPD Sharing Access Criteria
Data will be provided to academic-based researchers upon written request to the PI, Eric A. Hoffman, PhD. A nominal charge will be made for the time it takes for a technician to prepare and transfer the requested data. This costs will not exceed $250. This service will be available for a minimum of 2 years of study close.
Citations:
PubMed Identifier
20368443
Citation
Alford SK, van Beek EJ, McLennan G, Hoffman EA. Heterogeneity of pulmonary perfusion as a mechanistic image-based phenotype in emphysema susceptible smokers. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7485-90. doi: 10.1073/pnas.0913880107. Epub 2010 Apr 5.
Results Reference
result
PubMed Identifier
26569033
Citation
Iyer KS, Newell JD Jr, Jin D, Fuld MK, Saha PK, Hansdottir S, Hoffman EA. Quantitative Dual-Energy Computed Tomography Supports a Vascular Etiology of Smoking-induced Inflammatory Lung Disease. Am J Respir Crit Care Med. 2016 Mar 15;193(6):652-61. doi: 10.1164/rccm.201506-1196OC.
Results Reference
result
Available IPD and Supporting Information:
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
http://www.i-clic.uihc.uiowa.edu/
Available IPD/Information Identifier
Data Distribution

Learn more about this trial

Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema

We'll reach out to this number within 24 hrs